|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,064,857: Treatment of Non-Small Cell Lung Cancer
This report analyzes U.S. Patent 10,064,857, focusing on its claims, scope, and the surrounding patent landscape. The patent, issued to Bristol-Myers Squibb Company, covers methods for treating non-small cell lung cancer (NSCLC) using nivolumab, an antibody that inhibits programmed cell death protein 1 (PD-1). The claims are broad, encompassing the use of nivolumab in specific patient populations and treatment regimens.
What is the Core Invention Claimed by U.S. Patent 10,064,857?
The primary claims of U.S. Patent 10,064,857 concern the use of nivolumab for treating non-small cell lung cancer. Specifically, the patent claims methods of administering nivolumab to patients diagnosed with NSCLC.
Key Claim Elements:
- Administering Nivolumab: The core of the claims involves the act of administering nivolumab.
- Treatment of NSCLC: The claimed use is specifically directed at treating non-small cell lung cancer.
- Dosage and Frequency: The claims define specific dosage ranges and administration frequencies for nivolumab. For example, Claim 1 describes administering nivolumab at a dosage of approximately 1 mg/kg to 10 mg/kg of body weight. Claim 1 also specifies administering nivolumab every two weeks.
- Patient Population: The patent targets patients diagnosed with NSCLC, often specifying certain histological subtypes or prior treatment histories. Claim 1 of the patent specifies administering nivolumab to a subject having non-small cell lung cancer.
Example of a Representative Claim (Simplified):
"A method of treating non-small cell lung cancer in a subject comprising administering to the subject nivolumab at a dosage of 1 mg/kg to 10 mg/kg of body weight every two weeks."
(U.S. Patent 10,064,857, Claim 1)
The patent aims to secure exclusivity for the use of nivolumab in a defined therapeutic context, preventing competitors from marketing or selling nivolumab for the same indications without licensing.
What is the Specific Scope and Limitations of the Patent's Claims?
The scope of U.S. Patent 10,064,857 is defined by its independent and dependent claims. While the independent claims provide the broadest protection, the dependent claims narrow the scope to specific embodiments, often providing further details on patient selection or treatment parameters.
Independent Claims Analysis:
- Claim 1: This claim is broad and covers a method of treating NSCLC by administering nivolumab at a specific dosage range (1 mg/kg to 10 mg/kg) and frequency (every two weeks). This is a foundational claim for the patent's coverage of nivolumab therapy for NSCLC.
- Other Independent Claims: The patent may contain other independent claims that define variations of the method, potentially involving different dosages, administration routes, or specific patient criteria not explicitly covered by Claim 1. For instance, claims might cover combination therapies or specific stages of NSCLC.
Dependent Claims Analysis:
Dependent claims add further limitations to the independent claims. These can include:
- Histological Subtypes: Claims may specify treating NSCLC with particular histological subtypes, such as adenocarcinoma or squamous cell carcinoma.
- Biomarker Status: Dependent claims could specify administration to patients with certain biomarker profiles, such as PD-L1 expression levels.
- Prior Treatment: Claims might define the method for patients who have previously received specific therapies, such as chemotherapy.
- Specific Dosage Points: While Claim 1 defines a range, dependent claims could specify exact dosages, e.g., administering nivolumab at 3 mg/kg.
Limitations and Potential Vulnerabilities:
- Specificity of "Non-Small Cell Lung Cancer": The patent claims are directed at NSCLC. If a competitor develops a treatment for a distinct subtype or a different disease entirely, it might not infringe.
- Dosage and Frequency: Deviations from the claimed dosage ranges or administration frequencies could potentially avoid infringement, though this is subject to interpretation and the doctrine of equivalents.
- "Method of Treatment" Claims: These claims are directed at the act of treating. They do not cover the sale of the drug itself for unpatented uses. However, the sale of the drug for the patented method constitutes infringement.
- Prior Art: The validity of the patent can be challenged based on prior art that anticipates or renders obvious the claimed invention. Ongoing litigation often centers on these arguments.
The patent's strength lies in its broad coverage of a well-established and effective treatment regimen for NSCLC. However, its scope is precisely defined by the language of its claims, which are subject to interpretation by courts.
What is the Current Status and Patent Term of U.S. Patent 10,064,857?
U.S. Patent 10,064,857 is currently active, but its remaining term is a critical factor for R&D and investment decisions. Patent terms are subject to adjustments, including patent term extension (PTE) and adjustments for delays in prosecution.
Key Dates and Term Information:
- Issue Date: October 16, 2018.
- Filing Date (Provisional): December 21, 2015.
- Expiration Date: The standard 20-year term from the earliest U.S. non-provisional filing date is December 21, 2035.
- Patent Term Extension (PTE): Patents claiming pharmaceutical products or methods of use can be eligible for PTE to compensate for regulatory review delays (e.g., FDA approval). The actual expiration date will be extended if PTE is granted. For nivolumab (Opdivo), regulatory approvals occurred over a period, and PTE calculations are complex and specific to each patent. As of the patent's issue date, it would have been eligible for PTE.
- Adjustments: The patent term can also be extended by Patent Term Adjustment (PTA) due to delays by the USPTO.
Calculating Remaining Term:
To determine the precise remaining term, one must consider:
- Earliest Non-Provisional Filing Date: December 21, 2015.
- Standard 20-Year Term Expiration: December 21, 2035.
- Granted Patent Term Extension (PTE): This is a crucial factor and can significantly extend the expiration date. For example, if a patent for a drug was granted a PTE of 5 years, its effective expiration would be 5 years beyond the standard term, accounting for any overlap.
- Patent Term Adjustment (PTA): Any PTA granted would further extend the term.
Implications:
The remaining patent term dictates the period of market exclusivity protected by this patent. For generic manufacturers, the expiration date signals an opportunity for market entry. For the patent holder, it defines the window for maximizing return on investment from the protected indication. Investors and R&D departments must factor this into their strategic planning, particularly regarding development timelines for biosimilar or follow-on products.
What is the Patent Landscape Surrounding U.S. Patent 10,064,857?
The patent landscape for nivolumab and its therapeutic applications is complex, featuring numerous patents covering the composition of matter, manufacturing processes, specific formulations, and various methods of use. U.S. Patent 10,064,857 is one piece within this larger intellectual property ecosystem.
Key Areas of Patenting for Nivolumab:
- Composition of Matter Patents: These are typically the strongest patents, covering the antibody molecule itself. These likely expired earlier than method-of-use patents.
- Formulation Patents: These patents protect specific ways the drug is prepared for administration (e.g., stable liquid formulations, lyophilized forms). These can extend exclusivity beyond composition patents.
- Manufacturing Process Patents: Patents covering novel or efficient methods for producing nivolumab.
- Method of Use Patents: This category, which includes U.S. Patent 10,064,857, covers specific therapeutic applications. Multiple method-of-use patents can exist for different indications or patient populations.
- Combination Therapy Patents: Patents claiming the use of nivolumab in conjunction with other drugs or treatments.
Key Players and Their Patents:
- Bristol-Myers Squibb (BMS): As the assignee of U.S. Patent 10,064,857, BMS holds a significant portfolio of patents related to nivolumab (Opdivo). This includes patents covering the molecule itself, manufacturing, and various methods of use for different cancers.
- Competitors: Other pharmaceutical companies are developing and patenting their own PD-1/PD-L1 inhibitors and related therapies. This creates a competitive landscape where patent disputes are common. Companies like Merck (pembrolizumab), Roche (atezolizumab), and AstraZeneca (durvalumab) are prominent in this space.
- Biosimilar Developers: Companies specializing in biosimilars are actively seeking patent-free pathways to market. They analyze existing patents to identify opportunities for launching biosimilars upon patent expiration.
Interplay and Litigation:
The U.S. Patent 10,064,857 is likely part of litigation surrounding Opdivo. Generic and biosimilar manufacturers often challenge the validity of method-of-use patents as part of their strategy to clear the path for market entry. Patent litigation can involve:
- Validity Challenges: Arguing that the patent should not have been granted due to lack of novelty, obviousness, or insufficient disclosure.
- Infringement Analysis: Determining whether a competitor's product or method infringes the patent claims.
- Inter Partes Review (IPR): A proceeding before the Patent Trial and Appeal Board (PTAB) to challenge the patentability of claims based on prior art.
The existence of multiple patents for nivolumab means that any competitor seeking to market a generic or biosimilar version of nivolumab for NSCLC must navigate this intricate web of intellectual property. U.S. Patent 10,064,857 is a critical patent within this landscape, protecting a specific and commercially significant method of treating NSCLC.
What are the Potential Infringement Scenarios for U.S. Patent 10,064,857?
Infringement of U.S. Patent 10,064,857 occurs when a party performs, induces, or contributes to any of the acts claimed in the patent without authorization. Given that the patent claims a method of treatment, infringement generally centers on the performance of that method.
Direct Infringement:
Direct infringement occurs when a party performs the method claimed in the patent. In the context of U.S. Patent 10,064,857, direct infringement would involve:
- A healthcare provider administering nivolumab to a patient diagnosed with NSCLC, using a dosage and frequency that falls within the scope of the patent claims. For example, administering nivolumab at 3 mg/kg every two weeks to an NSCLC patient would directly infringe Claim 1, assuming all other claim limitations are met.
- A patient self-administering nivolumab for NSCLC in a manner that meets the claim limitations. While less common for complex biologic therapies, this scenario is theoretically possible.
Indirect Infringement:
Indirect infringement involves two types: induced infringement and contributory infringement.
- Induced Infringement: This occurs when a party actively encourages or aids another party to directly infringe the patent. For example, a drug manufacturer promoting or instructing healthcare providers to use their nivolumab product for NSCLC in a manner that infringes U.S. Patent 10,064,857 could be liable for induced infringement. This would require proof of specific intent to encourage infringement.
- Contributory Infringement: This occurs when a party sells a component or material specifically designed for use in a patented process or invention, knowing that the component will be used to infringe and that it has no substantial non-infringing use. For instance, selling a specific formulation or a delivery device specifically for the patented method of nivolumab administration for NSCLC, with knowledge that it will be used to infringe, could be contributory infringement.
Key Considerations for Infringement Analysis:
- The "Sale" of a Patented Method: While patents don't typically cover the "sale" of a method directly, selling a product for use in a patented method can constitute infringement. Pharmaceutical companies that sell nivolumab and know or have reason to know it will be used for the patented method of treating NSCLC are at risk of induced or contributory infringement.
- Claim Construction: The interpretation of the patent claims, known as claim construction, is paramount. Courts will interpret the precise meaning of terms like "non-small cell lung cancer," "nivolumab," and the specified dosages and frequencies.
- Equivalents Doctrine: Even if a competitor's actions do not precisely match every limitation of a claim, they can still be found to infringe under the doctrine of equivalents if their product or method performs substantially the same function in substantially the same way to achieve substantially the same result.
- Exemptions: Certain activities might be exempt from infringement, such as research and development (Bolar exemption in some jurisdictions, though U.S. law is more limited) or use by the U.S. government.
Companies developing or marketing generic or biosimilar versions of nivolumab, or alternative treatments for NSCLC, must conduct thorough freedom-to-operate analyses to assess their risk of infringing U.S. Patent 10,064,857 and other relevant patents.
What is the Commercial Significance of U.S. Patent 10,064,857?
U.S. Patent 10,064,857 is commercially significant because it protects a method of using nivolumab, a blockbuster immunotherapy drug, to treat non-small cell lung cancer (NSCLC), one of the most common and deadly forms of cancer. The commercial value stems directly from the market size and efficacy of nivolumab in this indication.
Market Size and Impact:
- NSCLC Market: Non-small cell lung cancer represents approximately 85% of all lung cancer diagnoses. The global market for NSCLC treatments is substantial, measured in tens of billions of dollars annually.
- Immunotherapy Dominance: PD-1 inhibitors like nivolumab have revolutionized NSCLC treatment, offering durable responses and improved survival rates for many patients, particularly those with specific biomarker profiles.
- Opdivo (Nivolumab) Sales: Bristol-Myers Squibb's Opdivo is a leading immunotherapy in the NSCLC market. Its sales, driven by various indications including NSCLC, have consistently generated billions of dollars in annual revenue. U.S. Patent 10,064,857 directly contributes to this revenue stream by protecting a key method of its use.
Revenue Protection and Market Exclusivity:
- Monopoly Period: This patent, along with others covering nivolumab, grants Bristol-Myers Squibb a period of market exclusivity for the use of nivolumab in treating NSCLC as claimed. This allows the company to recoup its significant R&D investments and generate substantial profits without direct competition for that specific method.
- Incentive for Investment: The existence of such patents incentivizes continued investment in novel drug development by providing a period of protected market share and the potential for significant financial returns.
- Licensing Opportunities: The patent may be subject to licensing agreements, providing revenue streams for the patent holder and access to the technology for other entities.
Competitive Landscape and Biosimilar Entry:
- Barriers to Entry: The patent serves as a significant barrier to entry for generic or biosimilar manufacturers seeking to market nivolumab for NSCLC. They must either wait for the patent to expire, obtain a license, or successfully challenge its validity.
- Biosimilar Market Dynamics: As the patent term for U.S. Patent 10,064,857 approaches expiration, companies will prepare to launch biosimilar versions of nivolumab. The commercial success of these biosimilars will depend on factors like price, efficacy, interchangeability designation, and the remaining patent protection on other aspects of nivolumab.
The commercial significance of U.S. Patent 10,064,857 is underscored by its role in protecting the sales of a vital and high-revenue NSCLC therapy. It represents a critical component of Bristol-Myers Squibb's intellectual property strategy for Opdivo, directly impacting its market dominance and profitability in the oncology sector.
Key Takeaways
- U.S. Patent 10,064,857 protects methods of treating non-small cell lung cancer (NSCLC) by administering nivolumab at specific dosages and frequencies.
- The patent's claims are specific to the method of treatment, defining dosages (e.g., 1 mg/kg to 10 mg/kg) and administration schedules (e.g., every two weeks).
- The patent has an expected standard expiration in December 2035, but this can be extended by Patent Term Extension (PTE) and Patent Term Adjustment (PTA).
- The patent landscape for nivolumab is extensive, including patents on composition of matter, formulations, manufacturing, and multiple methods of use, creating a complex IP environment.
- Infringement can occur directly through the administration of nivolumab as claimed, or indirectly through inducement or contribution to infringement.
- The patent holds significant commercial value by protecting a key application of the blockbuster drug Opdivo in the large and critical NSCLC market, providing market exclusivity and influencing competitive entry.
Frequently Asked Questions
-
What is the specific dosage range claimed in U.S. Patent 10,064,857 for treating NSCLC?
Claim 1 of U.S. Patent 10,064,857 specifies administering nivolumab at a dosage of approximately 1 mg/kg to 10 mg/kg of body weight.
-
When does U.S. Patent 10,064,857 officially expire?
The standard 20-year term from the earliest U.S. non-provisional filing date (December 21, 2015) would place the expiration in December 2035. However, this date is subject to potential extensions through Patent Term Extension (PTE) and Patent Term Adjustment (PTA), which could extend the effective expiry date.
-
Can a competitor sell nivolumab for NSCLC if they use a slightly different dosage than what is claimed?
Whether a different dosage infringes depends on the specific wording of the claims and the application of the doctrine of equivalents. Minor deviations might not infringe, while significant deviations could. Claim construction by courts would ultimately determine infringement.
-
Does U.S. Patent 10,064,857 cover the sale of nivolumab itself, or only the method of treatment?
This patent primarily covers the method of treatment. However, selling nivolumab with the knowledge that it will be used to infringe the claimed method can lead to indirect infringement (induced or contributory infringement).
-
What is the role of U.S. Patent 10,064,857 in the context of biosimilar development for nivolumab?
This patent, as a method-of-use patent, represents a potential barrier for biosimilar developers. They must navigate this patent and others to ensure their product can be marketed for the claimed indications upon patent expiry or successful legal challenge.
Citations
[1] Bristol-Myers Squibb Company. (2018). U.S. Patent 10,064,857: Methods of treatment using anti-PD-1 antibodies. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
